Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial-Reference-Cited by-同舟云学术

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial

Published:2015-02-28 Issue:14 Volume:6 Page:12796-12808
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Assenat Eric¹²,Azria David²³⁴⁵⁶,Mollevi Caroline²,Guimbaud Rosine⁷,Tubiana-Mathieu Nicole⁸,Smith Denis⁹,Delord Jean-Pierre¹⁰,Samalin Emmanuelle²,Portales Fabienne²,Larbouret Christel³⁴⁵⁶,Robert Bruno³⁴⁵⁶,Bibeau Frédéric²,Bleuse Jean-Pierre²,Crapez Evelyne²,Ychou Marc¹²³⁴⁵,Pèlegrin André³⁴⁵⁶

Affiliation:

1. Centre Hospitalier Régional Universitaire (CHU) de Montpellier, Montpellier, France

2. Institut Régional du Cancer de Montpellier (ICM)-Val d'Aurelle, Montpellier, France

3. IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France

4. INSERM, U896, Montpellier, France

5. Université Montpellier 1, Montpellier, France

6. Institut Régional du Cancer de Montpellier, ICM, Montpellier, France

7. Centre Hospitalier Universitaire (CHU) de Toulouse, TSA, Toulouse cedex, France

8. Centre Hospitalier Universitaire (CHU) de Limoges, Limoges cedex, France

9. Centre Hospitalier Universitaire (CHU) de Bordeaux, Talence cedex, France

10. Institut Claudius Régaud, Toulouse, France

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier;Cancer Treatment Reviews;2024-09

2. How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer;FUTURE ONCOL;2024

3. The trend toward more target therapy in pancreatic ductal adenocarcinoma;Expert Review of Anticancer Therapy;2024-05-23

4. Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC;Scientific Reports;2024-02-14

5. A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers;Onco;2023-05-26